IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides an update on IMAAGEN, a multicentre, open-label, single-arm, phase 2 trial evaluating the effect of abiraterone acetate plus prednisone on prostate specific antigen and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer without radiographic evidence of metastatic disease.

Year of Production:
Running Time:


Comments are closed.